Q2 2026 13F · SEC CIK 1616824
BML Capital Management, LLC
Hedge fundFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $175.1M
- Reported positions
- 15
- Top holdings a year, 3 yrs
- +22.2%
- Average holding period
- 2.1 yrs
BML Capital Management, LLC is a hedge fund that reported 15 positions worth $175.1M in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Aclaris Therapeutics Inc (ACRS, 36.2%), Atea Pharmaceuticals Inc (AVIR, 18.5%), Engene Therapeutics Inc (ENGN, 6.6%). A portfolio copying its top holdings returned 22.2% a year over the last 3 years, against 19.4% for the S&P 500.
BML Capital Management, LLC holdings all 15 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ACRSAclaris Therapeutics Inc | 36.2% | -16.0% | $63.3M |
| AVIRAtea Pharmaceuticals Inc | 18.5% | -1.5% | $32.3M |
| ENGNEngene Therapeutics Inc | 6.6% | — | $11.5M |
| KHCKraft Heinz Co | 6.3% | +272.0% | $11.0M |
| OMOutset Med Inc | 6.2% | +32.5% | $10.9M |
| KMXCarmax Inc | 5.2% | +11.3% | $9.1M |
| TLYSTilly's Inc Cl A | 5.2% | +0.0% | $9.0M |
| PMVPPmv Pharmaceuticals Inc | 4.1% | +0.2% | $7.1M |
| TILInstil Bio Inc | 2.8% | +0.0% | $5.0M |
| TGTTarget Corp | 2.8% | +0.0% | $4.9M |
| ORMPOramed Pharmaceuticals Inc | 2.4% | -72.6% | $4.2M |
| JANXJanux Therapeutics Inc | 1.4% | +0.0% | $2.4M |
| PLRXPliant Therapeutics Inc | 1.0% | +0.0% | $1.8M |
| CNTBConnect Biopharma Hldgs Ltd | 0.8% | +40.2% | $1.4M |
| IMAImagenebio Inc | 0.7% | +0.0% | $1.2M |
What BML Capital Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- ENGN Engene Therapeutics Inc6.6% of 13F
Added to
- KHC Kraft Heinz Co+272.0% shares
- CNTB Connect Biopharma Hldgs Ltd+40.2% shares
- OM Outset Med Inc+32.5% shares
- KMX Carmax Inc+11.3% shares
Reduced
- ORMP Oramed Pharmaceuticals Inc-72.6% shares
- ACRS Aclaris Therapeutics Inc-16.0% shares
Sold out
- KZR Kezar Life Sciences Incwas 3.4%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +144.7% /yr
- S&P 500 +22.0%
- 3 years
- +22.2% /yr
- S&P 500 +19.4%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $175.1M | 15 |
| Q1 2026 | $155.4M | 15 |
| Q4 2025 | $113.0M | 13 |
| Q3 2025 | $108.7M | 18 |
| Q2 2025 | $130.5M | 23 |
| Q1 2025 | $123.6M | 26 |
| Q4 2024 | $161.0M | 25 |
| Q3 2024 | $169.9M | 29 |
| Q2 2024 | $136.5M | 27 |
| Q1 2024 | $149.4M | 30 |
| Q4 2023 | $126.7M | 31 |
| Q3 2023 | $108.5M | 25 |
Questions about BML Capital Management, LLC's portfolio
What stocks does BML Capital Management, LLC own?
BML Capital Management, LLC's latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 15 positions worth $175.1M. The largest are Aclaris Therapeutics Inc (ACRS) at 36.2%, Atea Pharmaceuticals Inc (AVIR) at 18.5%, Engene Therapeutics Inc (ENGN) at 6.6%, Kraft Heinz Co (KHC) at 6.3% and Outset Med Inc (OM) at 6.2%.
What did BML Capital Management, LLC buy last quarter?
In Q2 2026, BML Capital Management, LLC added a new position in Engene Therapeutics Inc (ENGN), Kraft Heinz Co (KHC) (+272.0% shares), Connect Biopharma Hldgs Ltd (CNTB) (+40.2% shares) and Outset Med Inc (OM) (+32.5% shares), compared with its Q1 2026 filing.
What did BML Capital Management, LLC sell last quarter?
In Q2 2026, BML Capital Management, LLC sold all of Kezar Life Sciences Inc (KZR), Oramed Pharmaceuticals Inc (ORMP) (-72.6% shares) and Aclaris Therapeutics Inc (ACRS) (-16.0% shares), compared with its Q1 2026 filing.
How has BML Capital Management, LLC's portfolio performed?
A portfolio copying BML Capital Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +22.2% a year over the last 3 years, against +19.4% for the S&P 500. Over 1 year: +144.7% against +22.0%.
When is BML Capital Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. BML Capital Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.